Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Cervical Cancer Screening and Prevention in 78 Sexually Transmitted Disease Clinics-United States, 2014-2015.

McGinnis E, Meyerson BE, Meites E, Saraiya M, Griesse R, Snoek E, Haderxhanaj L, Markowitz LE, Smith W.

Sex Transm Dis. 2017 Oct;44(10):637-641. doi: 10.1097/OLQ.0000000000000659.

PMID:
28876317
2.

Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: Converging incidence in males and females.

Torre LA, Sauer AM, Chen MS Jr, Kagawa-Singer M, Jemal A, Siegel RL.

CA Cancer J Clin. 2016 May;66(3):182-202. doi: 10.3322/caac.21335. Epub 2016 Jan 14.

3.

Economic evaluation of DNA ploidy analysis vs liquid-based cytology for cervical screening.

Nghiem VT, Davies KR, Beck JR, Follen M, MacAulay C, Guillaud M, Cantor SB.

Br J Cancer. 2015 Jun 9;112(12):1951-7. doi: 10.1038/bjc.2015.95. Epub 2015 Apr 28.

4.

Cytology and human papillomavirus co-test results preceding incident high-grade cervical intraepithelial neoplasia.

Park IU, Wojtal N, Silverberg MJ, Bauer HM, Hurley LB, Manos MM.

PLoS One. 2015 Mar 20;10(3):e0118938. doi: 10.1371/journal.pone.0118938. eCollection 2015.

5.

Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology.

Agorastos T, Chatzistamatiou K, Katsamagkas T, Koliopoulos G, Daponte A, Constantinidis T, Constantinidis TC; HERMES study group.

PLoS One. 2015 Mar 20;10(3):e0119755. doi: 10.1371/journal.pone.0119755. eCollection 2015.

6.

Cervical cancer screening in a sexually transmitted disease clinic: screening adoption experiences from a midwestern clinic.

Meyerson BE, Sayegh MA, Davis A, Arno JN, Zimet GD, LeMonte AM, Williams JA, Barclay L, Van Der Pol B.

Am J Public Health. 2015 Apr;105 Suppl 2:e8-14. doi: 10.2105/AJPH.2014.302272. Epub 2015 Feb 17.

7.

Viral carcinogenesis: factors inducing DNA damage and virus integration.

Chen Y, Williams V, Filippova M, Filippov V, Duerksen-Hughes P.

Cancers (Basel). 2014 Oct 22;6(4):2155-86. doi: 10.3390/cancers6042155. Review.

8.

A lower degree of PBMC L1 methylation in women with lower folate status may explain the MTHFR C677T polymorphism associated higher risk of CIN in the US post folic acid fortification era.

Badiga S, Johanning GL, Macaluso M, Azuero A, Chambers MM, Siddiqui NR, Piyathilake CJ.

PLoS One. 2014 Oct 10;9(10):e110093. doi: 10.1371/journal.pone.0110093. eCollection 2014.

9.

New cervical cancer screening guidelines: was the annual pap too much of a good thing?

Fields MM.

J Adv Pract Oncol. 2013 Jan;4(1):59-64. Review. No abstract available.

10.

Mortality from sexually transmitted diseases in reproductive-aged women: United States, 1999-2010.

McElligott KA.

Am J Public Health. 2014 Aug;104(8):e101-5. doi: 10.2105/AJPH.2014.302044. Epub 2014 Jun 12.

11.

Cervical screening at age 50-64 years and the risk of cervical cancer at age 65 years and older: population-based case control study.

Castañón A, Landy R, Cuzick J, Sasieni P.

PLoS Med. 2014 Jan;11(1):e1001585. doi: 10.1371/journal.pmed.1001585. Epub 2014 Jan 14.

12.

Sexual behaviors and sexually transmitted infections in a nationally representative sample of women veterans and nonveterans.

Lehavot K, Katon JG, Williams EC, Nelson KM, Gardella CM, Reiber GE, Simpson TL.

J Womens Health (Larchmt). 2014 Mar;23(3):246-52. doi: 10.1089/jwh.2013.4327. Epub 2013 Dec 13.

13.

Urine-based human papillomavirus DNA testing as a screening tool for cervical cancer in high-risk women.

Mendez K, Romaguera J, Ortiz AP, López M, Steinau M, Unger ER.

Int J Gynaecol Obstet. 2014 Feb;124(2):151-5. doi: 10.1016/j.ijgo.2013.07.036. Epub 2013 Nov 1.

14.

Cervical neoplasia-related factors and decreased prevalence of uterine fibroids among a cohort of African American women.

Moore KR, Smith JS, Laughlin-Tommaso SK, Baird DD.

Fertil Steril. 2014 Jan;101(1):208-14. doi: 10.1016/j.fertnstert.2013.09.021. Epub 2013 Oct 23.

15.

HPV prevalence among women from Appalachia: results from the CARE project.

Reiter PL, Katz ML, Ruffin MT, Hade EM, DeGraffenreid CR, Patel DA, Paskett ED, Unger ER.

PLoS One. 2013 Aug 30;8(8):e74276. doi: 10.1371/journal.pone.0074276. eCollection 2013. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/7a4cfd0a-cf77-430e-89a0-b2576268e2eb.

16.

Modeling the impact of quadrivalent HPV vaccination on the incidence of Pap test abnormalities in the United States.

Chesson HW, Flagg EW, Koutsky L, Hsu K, Unger ER, Shlay JC, Kerndt P, Ghanem KG, Zenilman JM, Hagensee M, Weinstock H, Datta SD.

Vaccine. 2013 Jun 24;31(29):3019-24. doi: 10.1016/j.vaccine.2013.04.051. Epub 2013 May 10.

17.

Prevalence of high-risk human papilloma virus among women with hepatitis C virus before liver transplantation.

Tarallo PA, Smolowitz J, Carriero D, Tarallo J, Siegel A, Jia H, Emond JC.

Transpl Infect Dis. 2013 Aug;15(4):400-4. doi: 10.1111/tid.12086. Epub 2013 May 6.

18.

Cervical human papillomavirus infection in a sample of Hispanic women living in Puerto Rico: comparison with cervical cytology reports.

Méndez K, Romaguera J, Pérez CM, Soto-Salgado M, Tortolero-Luna G, Palefsky JM, Ortiz AP.

P R Health Sci J. 2013 Mar;32(1):3-7.

19.

Can clinical tests help monitor human papillomavirus vaccine impact?

Meites E, Lin C, Unger ER, Steinau M, Patel S, Markowitz LE, Hariri S.

Int J Cancer. 2013 Sep 1;133(5):1101-6. doi: 10.1002/ijc.28115. Epub 2013 Mar 13.

20.

Human papillomavirus genotypes detected in clinician-collected and self-collected specimens from women living in the Mississippi Delta.

Castle PE, Gage JC, Partridge EE, Rausa A, Gravitt PE, Scarinci IC.

BMC Infect Dis. 2013 Jan 7;13:5. doi: 10.1186/1471-2334-13-5.

Supplemental Content

Support Center